An FDA warning letter shows why product bundles, mixing instructions, and surrounding marketing can change the regulatory conversation for peptide businesses. Here is how to assess the risk without jumping to legal conclusions.
Dean Hamid, CLCS, AINS
PRIA Brokers — Peptide Insurance Specialist
Bacteriostatic water is often treated as a simple accessory in the broader peptide marketplace. But in a regulated-product review, an item does not always stand alone. How it is displayed, bundled, described, and fulfilled alongside other products can matter.
That is the practical concern behind what we call the “bacteriostatic water trap.” It is not a conclusion that every sale of bacteriostatic water is unlawful, or that one product listing establishes a company's intent. It is a reminder that surrounding commercial conduct can affect how regulators evaluate intended use and product status.
For peptide businesses, the relevant question is not simply, “What does this item say on its label?” It is also, “What does the complete customer journey communicate?”
In a March 31, 2026 warning letter to Gram Peptides, the FDA said it reviewed the firm's website from January through March 2026. The letter describes website offerings for Retatrutide and Tirzepatide products as well as “Bacteriostatic Water for Injection.”
The agency wrote: “The sale of these products together demonstrates that you intend for your ‘Bacteriostatic Water’ to be used in combination for injection. Therefore, your ‘Bacteriostatic Water’ is a drug.”
That language is significant because it focuses on the relationship among products. The FDA's position in that letter was based on the facts it described, including the products being offered together. It is not a court ruling, it does not establish that every seller has the same facts, and it should not be treated as a blanket rule for all bacteriostatic water sales.
Still, the letter offers a useful compliance signal: a regulatory review may examine the full context rather than accept “research use only” language in isolation.
Intended use can be informed by more than a single label statement. Depending on the facts, a regulator may look at promotional claims, product names, category pages, checkout suggestions, package inserts, social content, customer support scripts, and the way items are sold together.
For a peptide seller, risk may increase when a customer can readily connect an experimental compound to an injectable-use accessory through the seller's own materials. A customer does not need to receive an explicit medical instruction for the overall presentation to draw regulatory attention.
The concern becomes sharper when the surrounding materials appear to bridge the gap between a purported research product and human use. Examples of conduct that may merit legal and regulatory review include:
Product bundles or “frequently bought together” prompts that pair experimental peptides with bacteriostatic water or injection-related supplies.
Mixing, preparation, administration, or dosing content connected to products represented as research-only.
Marketing claims that reference weight loss, appetite, metabolic outcomes, patient results, or other human-use outcomes.
Cross-links, email sequences, customer-service responses, or social posts that give a buyer a practical path from purchase to use.
Inventory, fulfillment, or product descriptions that conflict with a company's stated research-only positioning.
These are risk indicators, not automatic violations. Their importance depends on the actual product, audience, statements, and regulatory setting. Qualified counsel should evaluate the facts of a specific operation.
The FDA has separately stated that retatrutide and cagrilintide cannot be used in compounding under federal law and are not components of FDA-approved drugs. That broader context raises the stakes for companies whose catalogues, marketing, or fulfillment practices appear to place those products in a human-use pathway.
The takeaway is not that businesses should infer legal status from a blog post or attempt to solve a regulatory question with website copy alone. It is that experimental-product offerings, injectable-use accessories, and human-use messaging can create a combined risk profile that deserves experienced review.
A thoughtful internal review should map what a reasonable customer sees before, during, and after a purchase. Consider reviewing:
Are product pages, bundles, upsells, and search results consistent with the company's stated positioning?
Do blogs, FAQs, videos, testimonials, or social posts suggest human use, directly or indirectly?
Are marketing claims reviewed before publication and archived after changes?
Are related items recommended, packaged, or shipped together in a way that could communicate a combined intended use?
Do order confirmations, support templates, insert cards, and post-purchase emails remain consistent with the compliance approach?
Are staff trained to route product-use questions rather than improvise an answer?
Is there a documented approval process for product descriptions, promotions, affiliate content, and customer communications?
Can the company demonstrate when pages changed, who approved them, and what corrective actions were taken?
Are distributors, affiliates, and other third parties subject to written marketing controls?
Good documentation does not eliminate regulatory risk. It can, however, support a more disciplined response when a carrier, regulator, marketplace, or business partner asks how controls are managed.
Regulatory questions can quickly become insurance questions. A warning letter, investigation, product withdrawal, or claim can expose gaps that a standard commercial policy may not address. Coverage varies materially by carrier and policy form, so the policy language controls.
When reviewing a program with a specialist, ask:
Does the policy contain exclusions related to pharmaceuticals, unapproved drugs, research chemicals, human-use allegations, or intentional acts?
Are defense costs for regulatory proceedings covered, limited, excluded, or available only by endorsement?
Does product liability coverage respond to the actual catalogue, sales channels, and jurisdictions involved?
Are recall, crisis-management, or product-withdrawal expenses included, and what events trigger them?
Have the business's website, affiliate, and fulfillment practices been accurately disclosed to the carrier?
Insurance is not a substitute for legal compliance, and it cannot retroactively change conduct or cure an exclusion. Clear disclosure and a coverage review before a problem arises are usually more valuable than assumptions after a claim is reported.
The FDA's Gram Peptides letter is a caution against evaluating bacteriostatic water, research-peptide claims, and marketing practices in separate silos. The agency's stated view was that the products it described being sold together demonstrated an intended injectable use. Other businesses may have different facts, but the enforcement signal is worth taking seriously.
If your business sells experimental peptides, bacteriostatic water, or related supplies, have qualified FDA and regulatory counsel review the complete customer journey. Then ask an insurance specialist to assess whether your disclosures and coverage match the operational risk you actually carry.
PRIA Brokers helps peptide businesses review insurance exposures involving products, distribution, marketing, and regulatory risk. Request a confidential coverage review or call (888) 998-7742.
This article is provided for general informational purposes only. It is not legal, regulatory, insurance, or medical advice and does not create a broker-client, attorney-client, or other professional relationship. Regulatory obligations and insurance coverage depend on the facts, jurisdiction, policy language, and current guidance. Consult qualified FDA/regulatory counsel and your insurance professional regarding your specific operations.
Partner Resource
Want to go deeper on peptide science?
The Peptide University covers compound profiles, protocols, and research — the essential complement to understanding your insurance needs.
PRIA Brokers specializes in coverage for peptide manufacturers, GLP-1 compounders, distributors, and suppliers. Compare quotes from A-rated specialty carriers.